Phase II Trial of Sterotactic Body Radiation Therapy (SBRT) for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common causes of global cancer death, with an increasing incidence in North America. Most patients are not suitable for surgery. Ablative therapies are an alternative treatment for some, but most patients have tumours too large for this. Stereotactic body radiation therapy (SBRT) refers to radiation therapy delivered precisely with a high dose volume conforming closely to the tumour, usually in less than 10 treatment fractions.
Patients are stratified into two groups of 17 (n=34) based on Child-Pugh Score [Child A56 vs. Child B78]. Individuals will be treated with six fractions of radiation to a total does of 30 to 54 Gy (in 5 to 9 Gy/fraction).
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society